Vista Capital Partners buys $276,058 stake in Amgen (AMGN)

Amgen (AMGN) : Vista Capital Partners scooped up 121 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 1,680 shares of Amgen which is valued at $276,058.Amgen makes up approximately 0.03% of Vista Capital Partners’s portfolio.

Other Hedge Funds, Including , Nisa Investment Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 6,774 additional shares and now holds a total of 308,415 shares of Amgen which is valued at $50,678,753. Amgen makes up approx 0.67% of Nisa Investment Advisors’s portfolio.Carroll Financial Associates boosted its stake in AMGN in the latest quarter, The investment management firm added 53 additional shares and now holds a total of 5,426 shares of Amgen which is valued at $913,250. Amgen makes up approx 0.14% of Carroll Financial Associates’s portfolio.Jacobs Coca boosted its stake in AMGN in the latest quarter, The investment management firm added 803 additional shares and now holds a total of 38,586 shares of Amgen which is valued at $6,494,410. Amgen makes up approx 1.46% of Jacobs Coca’s portfolio. Sadoff Investment Management added AMGN to its portfolio by purchasing 1,317 company shares during the most recent quarter which is valued at $220,598. Amgen makes up approx 0.02% of Sadoff Investment Management’s portfolio.Burns J W Co Incny boosted its stake in AMGN in the latest quarter, The investment management firm added 4,708 additional shares and now holds a total of 9,978 shares of Amgen which is valued at $1,668,721. Amgen makes up approx 0.52% of Burns J W Co Incny’s portfolio.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.